Diaceutics has reported results for 1H24 in accordance with the trading statement from July which translated into a net loss for the half of £2.6m with negative EBITDA of £1.3m. The reduced financials reflect the continuing high pace of development and data acquisition for the DXRX platform together with an increased focus on marketing, which raised costs; head count ended the period at 206, 28% higher YoY. However, the company reiterated its guidance that the two-year phase of accelerated investment is nearing completion and its expectation that the company will return to profitability and net free cash flow generation from 2025.